Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention.
Reads0
Chats0
TLDR
The authors in this paper summarized the current knowledge of IBD-CRC, focusing on the main mechanisms underlying its pathogenesis, and on the important role of immunomodulators and biologics used to treat IBD patients in interfering with the inflammatory process involved in carcinogenesis.Abstract:
Increased risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients has been attributed to long-standing chronic inflammation, with the contribution of genetic alterations and environmental factors such as the microbiota. Moreover, accumulating data indicate that IBD-associated CRC (IBD-CRC) may initiate and develop through a pathway of tumorigenesis distinct from that of sporadic CRC. This mini-review summarizes the current knowledge of IBD-CRC, focusing on the main mechanisms underlying its pathogenesis, and on the important role of immunomodulators and biologics used to treat IBD patients in interfering with the inflammatory process involved in carcinogenesis.read more
References
More filters
Journal ArticleDOI
Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis
Anouk M. Wijnands,Michiel E. de Jong,M. W. M. D. Lutgens,Frank Hoentjen,Sjoerd G. Elias,Bas Oldenburg +5 more
TL;DR: A systematic review and meta-analysis to identify all prognostic factors for advanced colorectal neoplasia (aCRN, high-grade dysplasia, or CRC) in patients with inflammatory bowel disease (IBD) was performed in this article.
Journal ArticleDOI
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis
TL;DR: 5- ASA has a chemopreventive effect on CRC (but not Dys) in IBD patients, and UC patients can benefit more from 5-ASA than CD patients.
Journal ArticleDOI
Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer.
TL;DR: Evaluation of changes in the gut microbiota during CRC development and progression offers a new strategy for the diagnosis and treatment of this disease.
Journal ArticleDOI
Clonal expansions in ulcerative colitis identify patients with neoplasia
Jesse J. Salk,Stephen J. Salipante,Rosa Ana Risques,David A. Crispin,Lin Li,Mary P. Bronner,Teresa A. Brentnall,Peter S. Rabinovitch,Marshall S. Horwitz,Lawrence A. Loeb +9 more
TL;DR: It is demonstrated that neutral mutations in polyguanine tracts serve as a unique tool for identifying fields of clonal expansions in patients with UC, which may prove clinically useful for distinguishing a subset of UC patients who are at risk for developing cancer.
Journal ArticleDOI
Colorectal carcinoma in the course of inflammatory bowel diseases
Andrzej Hnatyszyn,Szymon Hryhorowicz,Marta Kaczmarek-Ryś,Emilia Lis,Ryszard Słomski,Rodney J. Scott,Rodney J. Scott,Andrzej Pławski,Andrzej Pławski +8 more
TL;DR: An overview of the genetic and environmental factors that appear to influence both the occurrence of IBD and CRC with particular reference to NOD2 and TLRs as well as pro- and anti-inflammatory cytokines associated with tumor initiation and progression are shown, as they constitute potential targets for therapeutic intervention.
Related Papers (5)
The Role of Proinflammatory Pathways in the Pathogenesis of Colitis-Associated Colorectal Cancer.
Chengxin Luo,Hu Zhang +1 more